维布妥昔单抗治疗复发或难治性系统性间变性大细胞淋巴瘤的五年结果
这项关键2期研究评估维布妥昔单抗治疗复发或难治性系统性间变性大细胞淋巴瘤的安全性和疗效。自首次治疗起中位观察约6年,全部58例入组患者中40个月后未见进展,中位总生存未达到;经研究者评估的38例完全缓解患者中位总生存和无进展生存均未达到。33例发生周围神经病变,其中30例(91%)末次评估时已缓解或改善。
要点
- 全部58例患者40个月后未见疾病进展,中位总生存未达到。
- 38例(66%)完全缓解患者中位总生存和无进展生存均未达到。
- 33例周围神经病变患者中30例(91%)末次评估时缓解或改善。
核心结论
- 最终结果显示周围神经病变缓解率高,部分复发或难治性系统性间变性大细胞淋巴瘤患者获得持久缓解,提供证据表明单药维布妥昔单抗可能是潜在治愈性治疗选择。
研究设计与样本
- 关键2期研究,评估维布妥昔单抗治疗复发或难治性系统性间变性大细胞淋巴瘤,入组患者58例,自首次治疗起中位观察约6年。
- 试验注册号为NCT00866047。
主要发现
- 全部58例入组患者中40个月后未见进展,中位总生存未达到。
- 经研究者评估的完全缓解患者38例(66%),中位总生存和无进展生存均未达到。
- 38例完全缓解患者中16例接受巩固性干细胞移植,中位无进展生存未达到。
- 研究关闭时在研究内且处于缓解的患者中,16例除巩固性干细胞移植外未接受单药维布妥昔单抗后的任何新治疗,其中8例接受干细胞移植,其余8例(占全部入组患者的14%)未接受巩固性干细胞移植或任何新抗癌治疗仍维持持续缓解。
- 33例发生周围神经病变,其中30例(91%)末次评估时已缓解或改善。
临床怎么用
- 作者认为单药维布妥昔单抗可能是复发或难治性系统性间变性大细胞淋巴瘤的潜在治愈性治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This pivotal phase 2 study evaluated the safety and efficacy of brentuximab vedotin in patients with relapsed or refractory (R/R) systemic anaplastic large cell lymphoma (ALCL). After a median observation period of approximately 6 years from first treatment, we examined the durability of remission, progression-free survival (PFS), overall survival (OS), and safety outcomes of patients treated on this trial. Among all enrolled patients (n = 58), no progressions were observed beyond 40 months, and median OS was not reached. Patients with a complete response (CR), as assessed by the investigator (38 of 58, 66%), continued to demonstrate improved outcomes with neither median OS nor PFS reached. Of the 38 CR patients, 16 received a consolidative stem cell transplant (SCT) with median PFS not reached. Among patients who were on-study and in remission at study closure, 16 patients had not received any new treatment after single-agent brentuximab vedotin other than consolidative SCT. Among this subset of 16 patients, 8 received SCT, and the remaining 8 patients (14% of all enrolled patients) remained in sustained remission without consolidative SCT or any new anticancer therapy. Thirty-three patients experienced peripheral neuropathy, among whom, the majority (30 of 33, 91%) had experienced resolution or improvement at their last assessment. These final results, which demonstrated a high rate of peripheral neuropathy resolution, and durable remissions in a subset of patients with relapsed or refractory systemic ALCL, provide evidence that single-agent brentuximab vedotin may be a potentially curative treatment option. This trial was registered at www.clinicaltrials.gov as #NCT00866047.
引用
- Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017. PMID: 28974506. doi:10.1182/blood-2017-05-780049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。